Multicentre match-paired analysis of advanced biliary cancer long-term survivors : The BILONG study
Copyright © 2022 Elsevier Masson SAS. All rights reserved..
BACKGROUND: Advanced biliary cancers (ABC) are aggressive malignancies with a median overall survival (mOS) <12 months when treated with first-line chemotherapy. Nevertheless, a subset of patients experiencing longer survival has been described in the updated analysis of ABC-02 trial. We aimed to provide a real-world description of ABC long-term survivors (LS), identifying which factors impact on survival.
METHODS: Patients diagnosed with ABC at three Institutions between 2002 and 2019, and who survived ≥18 months, were retrospectively identified. We compared them with a control cohort (C) with a mOS <18 months, matched on age, gender, ECOG PS, disease status, primary tumor site, prior surgery, and treatment modality. Their clinical features, treatments, and outcome were analyzed.
RESULTS: A total of 78 patients was included, 39 in each group. Both LS and C cohorts had superimposable baseline characteristics, without significant differences. mOS was 29 (95%CI 24.6-33.5) and 9 months (95%CI 6.6-12.9) in the two groups, respectively. After performing a logistic regression analysis, three factors were significantly associated with long-term outcome: low neutrophil-to-lymphocyte ratio (NLR < 3) (Odds Ratio [OR] 0.38), achievement of objective response to treatment (OR 0.16), and the number of lines received (OR 0.29).
CONCLUSIONS: We described a considerable subset of ABC experiencing long-term survival with conventional chemotherapy in a real-world scenario. Beyond clinical factors, we identified low NLR as a prognostic determinant that may allow for a more accurate selection of long survivors. While waiting for a deeper molecular characterization of this subgroup, we propose NLR as a stratification factor for daily practice and clinical trials.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
|---|---|
| Enthalten in: |
Clinics and research in hepatology and gastroenterology - 46(2022), 8 vom: 24. Okt., Seite 101955 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Caputo, Francesco [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biliary cancer |
|---|
| Anmerkungen: |
Date Completed 05.10.2022 Date Revised 23.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clinre.2022.101955 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341322539 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341322539 | ||
| 003 | DE-627 | ||
| 005 | 20231226011518.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clinre.2022.101955 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1137.xml |
| 035 | |a (DE-627)NLM341322539 | ||
| 035 | |a (NLM)35609824 | ||
| 035 | |a (PII)S2210-7401(22)00092-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Caputo, Francesco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Multicentre match-paired analysis of advanced biliary cancer long-term survivors |b The BILONG study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.10.2022 | ||
| 500 | |a Date Revised 23.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a BACKGROUND: Advanced biliary cancers (ABC) are aggressive malignancies with a median overall survival (mOS) <12 months when treated with first-line chemotherapy. Nevertheless, a subset of patients experiencing longer survival has been described in the updated analysis of ABC-02 trial. We aimed to provide a real-world description of ABC long-term survivors (LS), identifying which factors impact on survival | ||
| 520 | |a METHODS: Patients diagnosed with ABC at three Institutions between 2002 and 2019, and who survived ≥18 months, were retrospectively identified. We compared them with a control cohort (C) with a mOS <18 months, matched on age, gender, ECOG PS, disease status, primary tumor site, prior surgery, and treatment modality. Their clinical features, treatments, and outcome were analyzed | ||
| 520 | |a RESULTS: A total of 78 patients was included, 39 in each group. Both LS and C cohorts had superimposable baseline characteristics, without significant differences. mOS was 29 (95%CI 24.6-33.5) and 9 months (95%CI 6.6-12.9) in the two groups, respectively. After performing a logistic regression analysis, three factors were significantly associated with long-term outcome: low neutrophil-to-lymphocyte ratio (NLR < 3) (Odds Ratio [OR] 0.38), achievement of objective response to treatment (OR 0.16), and the number of lines received (OR 0.29) | ||
| 520 | |a CONCLUSIONS: We described a considerable subset of ABC experiencing long-term survival with conventional chemotherapy in a real-world scenario. Beyond clinical factors, we identified low NLR as a prognostic determinant that may allow for a more accurate selection of long survivors. While waiting for a deeper molecular characterization of this subgroup, we propose NLR as a stratification factor for daily practice and clinical trials | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Biliary cancer | |
| 650 | 4 | |a Chemotherapy | |
| 650 | 4 | |a Cholangiocarcinoma | |
| 650 | 4 | |a Gallbladder cancer | |
| 650 | 4 | |a Long-term survivors | |
| 650 | 4 | |a Prognosis | |
| 650 | 4 | |a Survival | |
| 700 | 1 | |a Gelsomino, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Spallanzani, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Pettorelli, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Benatti, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Ghidini, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Grizzi, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Ratti, Margherita |e verfasserin |4 aut | |
| 700 | 1 | |a Merz, Valeria |e verfasserin |4 aut | |
| 700 | 1 | |a Messina, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Tonelli, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Luppi, Gabriele |e verfasserin |4 aut | |
| 700 | 1 | |a Melisi, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Dominici, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Salati, Massimiliano |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinics and research in hepatology and gastroenterology |d 2011 |g 46(2022), 8 vom: 24. Okt., Seite 101955 |w (DE-627)NLM201280868 |x 2210-741X |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2022 |g number:8 |g day:24 |g month:10 |g pages:101955 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clinre.2022.101955 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 46 |j 2022 |e 8 |b 24 |c 10 |h 101955 | ||